Abstract 1673P
Background
There is still a profound lack of efficient therapeutic strategies against pancreatic or other periampullary adenocarcinoma. Surgery is seldom possible, leaving palliative chemotherapy the only option for most patients. Chemotherapy treatment is however often accompanied by serious side-effects, and the identification of biomarkers for early prediction of disease and treatment-associated symptoms could help alleviate patient suffering. This study investigated the dynamic interrelationship between immune-related serum proteins, routine biomarkers and health-related quality of life (HRQoL) factors during chemotherapy treatment of patients enrolled in the prospective, observational study Chemotherapy, Host response And Molecular dynamics in Periampullary cancer (CHAMP).
Methods
Proximity extension assay was applied to analyse 92 immune-associated proteins in longitudinal serum samples from 75 patients, 18 being treated with adjuvant and 57 with palliative intent. HRQoL data were available from all patients at baseline (BL), from 41 patients at three months, and from 23 patients at six months.
Results
Levels of 8 proteins; CCL23, CD4, CD28, DCN, Gal-1, GZMB, GZMH and MMP7 were strongly correlated (Spearman´s Rho ≤-0.6 or ≥0.6) with various symptoms (insomnia, dyspnea, cognitive and emotional functioning) during treatment. Associations between routine laboratory parameters albumin, CA19-9, CEA and CRP and HRQoL were overall weaker. None of the investigated proteins were associated with pain.
Conclusions
This is, to our knowledge, the first study exploring associations between serum biomarkers and HRQoL in patients with pancreatic or other periampullary cancer, and some findings merit further validation. The proteoglycan decorin (DCN) is of particular interest as it has been linked to conditions such as Alzheimer’s disease and schizophrenia. Chemotherapy is known to cause persistent cognitive dysfunction with effects on memory and executive function, referred to as “chemo brain”. It would therefore be of great value to identify biomarkers for early detection and management of this debilitating condition.
Clinical trial identification
NCT03724994.
Editorial acknowledgement
Legal entity responsible for the study
Region Skåne.
Funding
This work is supported by peer reviewed grants from the Swedish Research Council (grant number 2015-03598 and 2018-02441), the Swedish Cancer Society (grant number CAN 2018/418 and 21 1596 Pj), the SjöbergFoundation, the Lennart GlansFoundation, BioCARE, the Mrs Berta KampradFoundation, the Ingrid and Sverker PerssonFoundation, the Faculty of Medicine, Lund University, Governmental Funding of Clinical Research (ALF), and Skåne University Hospital Donations and Funds.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1644P - The mutation landscape and evolution pattern of liver or peritoneal metastasis in pancreatic cancer
Presenter: Guoliang Yao
Session: Poster session 22
1645P - STAT3, ACTA2, and SPARC stromal markers predict response to Gemcitabine/Cisplatin/Nab-paclitaxel (GCN) in patients with advanced pancreatic adenocarcinoma (apdac)
Presenter: Himil Mahadevia
Session: Poster session 22
1646P - Genomic and prognostic differences in patients with different KRAS mutations in pancreatic cancer
Presenter: Chunwei Xu
Session: Poster session 22
1647P - Cancer-associated endocrine cell: A novel component of tumor microenvironment in pancreatic cancer
Presenter: Yuan Chen
Session: Poster session 22
1648P - Association between circulating tumor cell count and thrombosis in pancreatic cancer
Presenter: Monica Benavente
Session: Poster session 22
1649P - Comprehensive genomic profiling contributes to the prognosis of patients with advanced pancreatic cancer
Presenter: Eiichiro So
Session: Poster session 22
1650P - Identification of potential targets in pancreatic adenocarcinoma: The KRAS Wild-Type subset
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1651P - Comparison of surgical outcome and prognostic factors between pancreaticobiliary and intestinal types of periampullary adenocarcinoma following pancreaticoduodenectomy
Presenter: Saad Anwar
Session: Poster session 22
1652P - Interaction between enhanced cytokine signalling and ferroptosis defence fuels obesity-associated pancreatic ductal adenocarcinoma oncogenesis
Presenter: Rishat Ruzi
Session: Poster session 22
1653P - The activated thermogenesis of intra-pancreatic fat fuels the progression of pancreatic cancer
Presenter: Xi'n'peng Yin
Session: Poster session 22